Announcements

MDPI will attend the ESMO Congress 2023 as an exhibitor. This conference will be held in Madrid, Spain, from 20 to 24 October 2023.

The ESMO Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. They will disseminate the latest cutting-edge data, provide high-quality education and unparalleled networking opportunities for oncologists and other stakeholders from all around the world.

The following MDPI journals will be represented:

• Cancers;
• JCM;
• Cells;
• Diagnostics;
• Medical Sciences;
• Biomedicines;
• Geriatrics;
• Current Oncology;
• Hemato;
• Onco;
• CIMB;
• Healthcare.

If you are attending this conference, please feel free to start a conversation with us at our booth #724. Our delegates look forward to meeting you in person and answering any questions that you may have.

For more information about the conference, please visit https://www.esmo.org/meeting-calendar/esmo-congress-2023.

The 2022 citation metrics have been released in the Journal Citation Reports (JCR), and we’re pleased to announce the following results for MDPI journals:

We are thrilled to announce that 90% of our ranked MDPI journals, specifically 86 out of 96 (captured in the table below), are performing above average in Q1 or Q2. This year, Clarivate has expanded its Impact Factor (IF) awards to include journals in the Emerging Sources Citation Index (ESCI) and the Arts and Humanities Citation Index (AHCI), providing greater transparency for the full set of journals indexed in the Web of Science Core Collection. As a result, 111 of MDPI journals have received their first IF in 2023, with 37 journals surpassing an IF of 3.0. In total, 208 MDPI journals have been honored with an IF.

Clarivate explains that by "expanding the coverage but holding to highly selective standards, the [Impact Factor] is now a reliable indicator of trustworthiness, as well as a measure of scholarly impact, at the journal level."

Please visit our blog post where we discuss the release of the latest citation metrics with our Indexing Manager, Dr. Constanze Schelhorn, to find out what's different this time around and how to make use of different metrics available.

Note: The Journal of Personalized Medicine's Impact Factor was omitted in the original release and will be assigned separately. Please find the data on the journal webpage in due course.

Source: 2022 Journal Impact Factors, Journal Citation Reports ^TM (Clarivate, 2023)

As Current Oncology (ISSN: 1718-7729) is of open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers of the Section “Gastrointestinal Oncology” shown below:

1. “Immunotherapy in Gastric Cancer”
by Anica Högner and Markus Moehler
Curr. Oncol. 2022, 29(3), 1559–1574; https://doi.org/10.3390/curroncol29030131
Available online: https://www.mdpi.com/1718-7729/29/3/131

2. “Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI”
by Jelena Djokic Kovač, Aleksandra Janković, Aleksandra Đikić-Rom, Nikica Grubor, Andrija Antić and Vladimir Dugalić
Curr. Oncol. 2022, 29(2), 698–723; https://doi.org/10.3390/curroncol29020061
Available online: https://www.mdpi.com/1718-7729/29/2/61

3. “Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma”
by Tadahisa Inoue, Itaru Naitoh, Rena Kitano, Mayu Ibusuki, Yuji Kobayashi, Yoshio Sumida, Yukiomi Nakade, Kiyoaki Ito and Masashi Yoneda
Curr. Oncol. 2022, 29(4), 2240–2251; https://doi.org/10.3390/curroncol29040182
Available online: https://www.mdpi.com/1718-7729/29/4/182

4. “Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy”
by Davide Giuseppe Ribaldone, Gian Paolo Caviglia, Silvia Gaia, Emanuela Rolle, Alessandra Risso, Daniela Campion, Paola Rita Brunocilla, Giorgio Maria Saracco and Patrizia Carucci
Curr. Oncol. 2022, 29(3), 1422–1429; https://doi.org/10.3390/curroncol29030119
Available online: https://www.mdpi.com/1718-7729/29/3/119

5. “Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies”
by Miguel A. Ortega, Leonel Pekarek, Oscar Fraile-Martinez, Cielo Garcia-Montero, Miguel A. Saez, Angel Asúnsolo, Miguel A. Alvarez-Mon, Jorge Monserrat, Lidia Ruiz-Llorente, Natalio García-Honduvilla et al.
Curr. Oncol. 2022, 29(4), 2442–2453; https://doi.org/10.3390/curroncol29040198
Available online: https://www.mdpi.com/1718-7729/29/4/198

6. “Immunotherapy in Squamous Cell Cancer of the Esophagus”
by Peter Thuss-Patience and Alexander Stein
Curr. Oncol. 2022, 29(4), 2461–2471; https://doi.org/10.3390/curroncol29040200
Available online: https://www.mdpi.com/1718-7729/29/4/200

7. “Tumor Stroma Ratio and Its Significance in Locally Advanced Colorectal Cancer”
by Luz Sullivan, Richard R. Pacheco, Michel Kmeid, Anne Chen and Hwajeong Lee
Curr. Oncol. 2022, 29(5), 3232–3241; https://doi.org/10.3390/curroncol29050263
Available online: https://www.mdpi.com/1718-7729/29/5/263

8. “Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes”
by Nicolas Voizard, Tiffany Ni, Alex Kiss, Robyn Pugash, Michael Jonathon Raphael, Natalie Coburn and Elizabeth David
Curr. Oncol. 2022, 29(1), 209–220; https://doi.org/10.3390/curroncol29010020 
Available online: https://www.mdpi.com/1718-7729/29/1/20

9. “An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer”
by Alessandra Anna Prete, Letizia Procaccio, Francesca Bergamo, Cosimo Rasola, Floriana Nappo, Vittorina Zagonel and Sara Lonardi
Curr. Oncol. 2022, 29(2), 544–550; https://doi.org/10.3390/curroncol29020049
Available online: https://www.mdpi.com/1718-7729/29/2/49

10. “In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma”
by Yue Wang, Xulong Huang, Siyu Chen, Huajuan Jiang, Huanan Rao, Lijie Lu, Feiyan Wen and Jin Pei
Curr. Oncol. 2022, 29(9), 6573–6593; https://doi.org/10.3390/curroncol29090517
Available online: https://www.mdpi.com/1718-7729/29/9/517

As Current Oncology (ISSN: 1718-7729) is of open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers of the Section “Head and Neck Oncology” shown below:

1. “Osseous Union after Mandible Reconstruction with Fibula Free Flap Using Manually Bent Plates vs. Patient-Specific Implants: A Retrospective Analysis of 89 Patients”
by Michael Knitschke, Sophia Sonnabend, Fritz Christian Roller, Jörn Pons-Kühnemann, Daniel Schmermund, Sameh Attia, Philipp Streckbein, Hans-Peter Howaldt and Sebastian Böttger
Curr. Oncol. 2022, 29(5), 3375–3392; https://doi.org/10.3390/curroncol29050274
Available online: https://www.mdpi.com/1718-7729/29/5/274

2. “Rates of Smoking Cessation at 6 and 12 Months after a Clinical Tobacco Smoking Cessation Intervention in Head and Neck Cancer Patients in Northern Ontario, Canada”
by Stacey A. Santi, Michael S. C. Conlon, Margaret L. Meigs, Stacey M. Davidson, Kyle Mispel-Beyer and Deborah P. Saunders
Curr. Oncol. 2022, 29(3), 1544–1558; https://doi.org/10.3390/curroncol29030130
Available online: https://www.mdpi.com/1718-7729/29/3/130

3. “Co-Occurrence of EBV-Positive Mucocutaneous Ulcer (EBV-MCU) and CLL/SLL in the Head and Neck Region”
by Patricia Bott, Ilske Oschlies, Andreas Radeloff and Maureen Loewenthal
Curr. Oncol. 2022, 29(4), 2749–2767; https://doi.org/10.3390/curroncol29040224
Available online: https://www.mdpi.com/1718-7729/29/4/224

4. “Prognostic and Predictive Relevance of Tumor-Infiltrating Lymphocytes in Squamous Cell Head–Neck Cancer Patients Treated with Radical Radiotherapy/Chemo-Radiotherapy”
by Ioannis M. Koukourakis, Anastasia G. Gkegka, Erasmia Xanthopoulou, Christos Nanos, Alexandra Giatromanolaki and Michael I. Koukourakis
Curr. Oncol. 2022, 29(6), 4274–4284; https://doi.org/10.3390/curroncol29060342
Available online: https://www.mdpi.com/1718-7729/29/6/342

5. “Impact of Nutrition Counseling in Head and Neck Cancer Sufferers Undergoing Antineoplastic Therapy: A Randomized Controlled Pilot Study”
by Wangshu Dai, Shu-An Wang, Kongcheng Wang, Chen Chen, Juan Wang, Xiaotian Chen and Jing Yan
Curr. Oncol. 2022, 29(10), 6947–6955; https://doi.org/10.3390/curroncol29100546
Available online: https://www.mdpi.com/1718-7729/29/10/546

6. “Outcomes of Early Transition of Low-Risk Thyroid Cancer Patients from Specialist to Primary Care”
by Patricia Nguyen, Parsa Azizi-Mehr, Carol Townsley and Afshan Zahedi
Curr. Oncol. 2022, 29(10), 7672–7679; https://doi.org/10.3390/curroncol29100606
Available online: https://www.mdpi.com/1718-7729/29/10/606

7. “Influence of Tumor Site on Survival in Young Patients with Head and Neck Squamous Cell Carcinoma”
by Claudius Steffen, Iris Piwonski, Max Heiland, Carmen Stromberger, Grzegorz Kofla, Christian Doll, Annekatrin Coordes and Benedicta Beck-Broichsitter
Curr. Oncol. 2022, 29(2), 969–980; https://doi.org/10.3390/curroncol29020082
Available online: https://www.mdpi.com/1718-7729/29/2/82

8. “Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer”
by Justus Baumgarten, Christian Happel, Daniel Groener, Jennifer Staudt, Benjamin Bockisch, Amir Sabet, Frank Grünwald and Thomas Rink
Curr. Oncol. 2022, 29(6), 4012–4019; https://doi.org/10.3390/curroncol29060320
Available online: https://www.mdpi.com/1718-7729/29/6/320

9. “The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases”
by Zainul-Abedin Kapacee, Jennifer Allison, Mohammed Dawod, Xin Wang, Melissa Frizziero, Bipasha Chakrabarty, Prakash Manoharan, Catherine McBain, Was Mansoor, Angela Lamarca et al.
Curr. Oncol. 2022, 29(7), 5110–5125; https://doi.org/10.3390/curroncol29070405
Available online: https://www.mdpi.com/1718-7729/29/7/405

10. “A Qualitative Study of Patient and Healthcare Provider Perspectives on Building Multiphasic Exercise Prehabilitation into the Surgical Care Pathway for Head and Neck Cancer”
by Julia T. Daun, Rosie Twomey, Joseph C. Dort, Lauren C. Capozzi, Trafford Crump, George J. Francis, T. Wayne Matthews, Shamir P. Chandarana, Robert D. Hart, Christiaan Schrag et al.
Curr. Oncol. 2022, 29(8), 5942–5954; https://doi.org/10.3390/curroncol29080469
Available online: https://www.mdpi.com/1718-7729/29/8/469

Conference: 29th Congress of the European Association for Cancer Research
Date: 12–15 June 2023
Place: Torino, Italy

MDPI will be attending the 29th Congress of the European Association for Cancer Research, held in Torino, Italy, from 12 to 15 June 2023. This conference aims to achieve an in-depth exchange of the latest research results in the field of basic research, clinical application, cutting-edge technology, and industrial development in the field of cancer research over the year. During this conference, MDPI will welcome researchers from different backgrounds to visit and share their latest ideas with us.

The following MDPI journals will be represented:

• Cells;
• Cancers;
• Children;
• CIMB;
• Current Oncology;
• Diagnostics;
• Geriatrics;
• Healthcare;
• JCM;
• Medical Sciences.

If you are attending this conference, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://www.eacr2023.org/.

1. “Immune Checkpoint Inhibitors in Cancer Therapy”
by Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, Seyed Reza Hosseini-Fard, Shadi Hosseini, Habib Sadeghirad, Rahul Ladwa, Ken O’Byrne and Arutha Kulasinghe
Curr. Oncol. 2022, 29(5), 3044–3060; https://doi.org/10.3390/curroncol29050247
Available online: https://www.mdpi.com/1718-7729/29/5/247

2. “Immunotherapy in Gastric Cancer”
by Anica Högner and Markus Moehler
Curr. Oncol. 2022, 29(3), 1559–1574; https://doi.org/10.3390/curroncol29030131
Available online: https://www.mdpi.com/1718-7729/29/3/131

3. “Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer”
by Valentina K. Todorova, Stephanie D. Byrum, Allen J. Gies, Cade Haynie, Hunter Smith, Nathan S. Reyna and Issam Makhoul
Curr. Oncol. 2022, 29(2), 613–630; https://doi.org/10.3390/curroncol29020055
Available online: https://www.mdpi.com/1718-7729/29/2/55

4. “Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review”
by Samiha Mohsen, Philip T. Sobash, Ghada Fahad Algwaiz, Noor Nasef, Safaa Abed Al-Zeidaneen and Nagla Abdel Karim
Curr. Oncol. 2022, 29(3), 1695–1708; https://doi.org/10.3390/curroncol29030141
Available online: https://www.mdpi.com/1718-7729/29/3/141

5. “Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology”
by Hamid Mithoowani and Michela Febbraro
Curr. Oncol. 2022, 29(3), 1828–1839; https://doi.org/10.3390/curroncol29030150
Available online: https://www.mdpi.com/1718-7729/29/3/150

6. “A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature”
by Adrian J. M. Bailey, Aidan M. Kirkham, Madeline Monaghan, Risa Shorr, C. Arianne Buchan, Christopher Bredeson and David S. Allan
Curr. Oncol. 2022, 29(1), 337–349; https://doi.org/10.3390/curroncol29010030
Available online: https://www.mdpi.com/1718-7729/29/1/30

7. “Exosomal Non-Coding RNAs: New Insights into the Biology of Hepatocellular Carcinoma”
by Qian Zhang, Hanlin Li, Yang Liu, Jian Li, Chunling Wu and Hua Tang
Curr. Oncol. 2022, 29(8), 5383–5406; https://doi.org/10.3390/curroncol29080427
Available online: https://www.mdpi.com/1718-7729/29/8/427

8. “Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence”
by Ilaria Attili, Antonio Passaro, Pasquale Pisapia, Umberto Malapelle and Filippo de Marinis
Curr. Oncol. 2022, 29(1), 255–266; https://doi.org/10.3390/curroncol29010024
Available online: https://www.mdpi.com/1718-7729/29/1/24

9. “Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art”
by Gianluigi Califano, Idir Ouzaid, Paul Laine-Caroff, Arthur Peyrottes, Claudia Collà Ruvolo, Benjamin Pradère, Vincent Elalouf, Vincent Misrai, Jean-François Hermieu, Shahrokh F. Shariat et al.
Curr. Oncol. 2022, 29(2), 687–697; https://doi.org/10.3390/curroncol29020060
Available online: https://www.mdpi.com/1718-7729/29/2/60

10. “Endometrial Cancer: Transitioning from Histology to Genomics”
by Cristina Mitric and Marcus Q. Bernardini
Curr. Oncol. 2022, 29(2), 741–757; https://doi.org/10.3390/curroncol29020063
Available online: https://www.mdpi.com/1718-7729/29/2/63

11. “Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article”
by Chieh-Hsun Chen, Hsin-Su Yu and Sebastian Yu
Curr. Oncol. 2022, 29(4), 2871–2886; https://doi.org/10.3390/curroncol29040234
Available online: https://www.mdpi.com/1718-7729/29/4/234

12. “Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond”
by Maple Ye Feng, Landon L. Chan and Stephen Lam Chan
Curr. Oncol. 2022, 29(8), 5489–5507; https://doi.org/10.3390/curroncol29080434
Available online: https://www.mdpi.com/1718-7729/29/8/434

13. “Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis”
by Salvatore Cozzi, Masoumeh Najafi, Marzieh Gomar, Patrizia Ciammella, Cinzia Iotti, Corrado Iaccarino, Massimo Dominici, Giacomo Pavesi, Chiara Chiavelli, Ali Kazemian et al.
Curr. Oncol. 2022, 29(2), 881–891; https://doi.org/10.3390/curroncol29020075
Available online: https://www.mdpi.com/1718-7729/29/2/75

14. “Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care”
by Brandon S. Sheffield, Andrea Beharry, Joanne Diep, Kirstin Perdrizet, Marco A. J. Iafolla, William Raskin, Shaan Dudani, Mary Anne Brett, Blerta Starova, Brian Olsen et al.
Curr. Oncol. 2022, 29(3), 1326–1334; https://doi.org/10.3390/curroncol29030113
Available online: https://www.mdpi.com/1718-7729/29/3/113

15. “Applications of Artificial Intelligence in Screening, Diagnosis, Treatment, and Prognosis of Colorectal Cancer”
by Hang Qiu, Shuhan Ding, Jianbo Liu, Liya Wang and Xiaodong Wang
Curr. Oncol. 2022, 29(3), 1773–1795; https://doi.org/10.3390/curroncol29030146
Available online: https://www.mdpi.com/1718-7729/29/3/146

1. “Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far?”
by Luigi Bennardo, Francesco Bennardo, Amerigo Giudice, Maria Passante, Stefano Dastoli, Pietro Morrone, Eugenio Provenzano, Cataldo Patruno and Steven Paul Nisticò
Curr. Oncol. 2021, 28(4), 2317–2325; https://doi.org/10.3390/curroncol28040213
Available online: https://www.mdpi.com/1718-7729/28/4/213

2. “COVID-19 Pandemic Stressors and Psychological Symptoms in Breast Cancer Patients”
by Véronique Massicotte, Hans Ivers and Josée Savard
Curr. Oncol. 2021, 28(1), 294–300; https://doi.org/10.3390/curroncol28010034
Available online: https://www.mdpi.com/1718-7729/28/1/34 

3. “The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review”
by Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald and Beverley Essue
Curr. Oncol. 2021, 28(2), 1216–1248; https://doi.org/10.3390/curroncol28020117
Available online: https://www.mdpi.com/1718-7729/28/2/117

4. “Artificial Intelligence in Colorectal Cancer Screening, Diagnosis and Treatment. A New Era”
by Athanasia Mitsala, Christos Tsalikidis, Michail Pitiakoudis, Constantinos Simopoulos and Alexandra K. Tsaroucha
Curr. Oncol. 2021, 28(3), 1581–1607; https://doi.org/10.3390/curroncol28030149
Available online: https://www.mdpi.com/1718-7729/28/3/149

5. “Synovial Sarcoma: A Clinical Review”
by Aaron M. Gazendam, Snezana Popovic, Sohaib Munir, Naveen Parasu, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(3), 1909–1920; https://doi.org/10.3390/curroncol28030177
Available online: https://www.mdpi.com/1718-7729/28/3/177

6. “Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives”
by Jonathan M. Loree, Hallie Dau, Nevena Rebić, Alyssa Howren, Louise Gastonguay, Helen McTaggart-Cowan, Sharlene Gill, Kanwal Raghav and Mary A. De Vera
Curr. Oncol. 2021, 28(1), 671–677; https://doi.org/10.3390/curroncol28010065
Available online: https://www.mdpi.com/1718-7729/28/1/65

7. “Current Overview of Treatment for Metastatic Bone Disease”
by Shinji Tsukamoto, Akira Kido, Yasuhito Tanaka, Giancarlo Facchini, Giuliano Peta, Giuseppe Rossi and Andreas F. Mavrogenis
Curr. Oncol. 2021, 28(5), 3347–3372; https://doi.org/10.3390/curroncol28050290
Available online: https://www.mdpi.com/1718-7729/28/5/290

8. “Extramammary Paget’s Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments”
by Shoichiro Ishizuki and Yoshiyuki Nakamura
Curr. Oncol. 2021, 28(4), 2969–2986; https://doi.org/10.3390/curroncol28040260
Available online: https://www.mdpi.com/1718-7729/28/4/260

9. “Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults”
by D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska et al.
Curr. Oncol. 2021, 28(1), 523–548; https://doi.org/10.3390/curroncol28010053
Available online: https://www.mdpi.com/1718-7729/28/1/53

10. “The Feasibility and Effects of a Telehealth-Delivered Home-Based Prehabilitation Program for Cancer Patients during the Pandemic”
by Fiona Wu, Oloruntobi Rotimi, Roberto Laza-Cagigas and Tarannum Rampal
Curr. Oncol. 2021, 28(3), 2248–2259; https://doi.org/10.3390/curroncol28030207
Available online: https://www.mdpi.com/1718-7729/28/3/207 

11. “Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists”
by Angel A. T. Uchiyama, Pedro A. I. A. Silva, Moisés S. M. Lopes, Cheng T. Yen, Eliza D. Ricardo, Taciana Mutão, Jefferson R. Pimenta, Larissa M. Machado, Denis S. Shimba and Renata D. Peixoto
Curr. Oncol. 2021, 28(1), 783–799; https://doi.org/10.3390/curroncol28010076
Available online: https://www.mdpi.com/1718-7729/28/1/76

12. “Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer”
by Samitha Andrahennadi, Amer Sami, Mita Manna, Mehrnoosh Pauls and Shahid Ahmed
Curr. Oncol. 2021, 28(3), 1803–1822; https://doi.org/10.3390/curroncol28030168
Available online: https://www.mdpi.com/1718-7729/28/3/168

13. “Psychosocial Distress in Adult Patients Awaiting Cancer Surgery during the COVID-19 Pandemic”
by David Forner, Sarah Murnaghan, Geoffrey Porter, Ross J. Mason, Paul Hong, S. Mark Taylor, James Bentley, Gregory Hirsch, Christopher W. Noel, Matthew H. Rigby et al.
Curr. Oncol. 2021, 28(3), 1867–1878; https://doi.org/10.3390/curroncol28030173
Available online: https://www.mdpi.com/1718-7729/28/3/173

14. “Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients”
by Sébastien Perreault, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan D. Wasserman et al.
Curr. Oncol. 2021, 28(1), 346–366; https://doi.org/10.3390/curroncol28010038
Available online: https://www.mdpi.com/1718-7729/28/1/38

15. “Detection of Cervical Cancer Cells in Whole Slide Images Using Deformable and Global Context Aware Faster RCNN-FPN”
by Xia Li, Zhenhao Xu, Xi Shen, Yongxia Zhou, Binggang Xiao and Tie-Qiang Li
Curr. Oncol. 2021, 28(5), 3585–3601; https://doi.org/10.3390/curroncol28050307
Available online: https://www.mdpi.com/1718-7729/28/5/307

16. “Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects”
by Grace Lassiter, Cole Bergeron, Ryan Guedry, Julia Cucarola, Adam M. Kaye, Elyse M. Cornett, Alan D. Kaye, Giustino Varrassi, Omar Viswanath and Ivan Urits
Curr. Oncol. 2021, 28(1), 640–660; https://doi.org/10.3390/curroncol28010063
Available online: https://www.mdpi.com/1718-7729/28/1/63

17. “Advancing the Field of Pediatric Exercise Oncology: Research and Innovation Needs”
by Amanda Wurz, Emma McLaughlin, Carolina Chamorro Viña, Sarah L. Grimshaw, Lotta Hamari, Miriam Götte, Sabine Kesting, Francesca Rossi, Patrick van der Torre, Gregory M. T. Guilcher et al.
Curr. Oncol. 2021, 28(1), 619–629; https://doi.org/10.3390/curroncol28010061
Available online: https://www.mdpi.com/1718-7729/28/1/61

18. “The Advances and Challenges of NK Cell-Based Cancer Immunotherapy”
by Synat Kang, Xuefeng Gao, Li Zhang, Erna Yang, Yonghui Li and Li Yu
Curr. Oncol. 2021, 28(2), 1077–1093; https://doi.org/10.3390/curroncol28020105
Available online: https://www.mdpi.com/1718-7729/28/2/105

19. “Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study”
by Katie Mycock, Lin Zhan, Gavin Taylor-Stokes, Gary Milligan and Debanjali Mitra
Curr. Oncol. 2021, 28(1), 678–688; https://doi.org/10.3390/curroncol28010066
Available online: https://www.mdpi.com/1718-7729/28/1/66

20. “Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?”
by Mitchell Sabloff, Steven Tisseverasinghe, Mustafa Ege Babadagli and Rajiv Samant
Curr. Oncol. 2021, 28(1), 903–917; https://doi.org/10.3390/curroncol28010089
Available online: https://www.mdpi.com/1718-7729/28/1/89

This conference organized by the British Pharmacological Society and International Union of Basic and Clinical Pharmacologists (IUPHAR) will be held in Glasgow, Scotland, from 2 July to 7 July 2023. The topic of the conference focuses on pharmacology and drug discovery, research, and development, and the conference will include six days of symposia, keynote lectures, workshops, and debates. Discover the latest in pharmacology research and developments across 10 content themes.

Pharmaceuticals (ISSN: 1424-8247) is a peer-reviewed, open access journal of medicinal chemistry and related drug sciences, published monthly online by MDPI. Pharmaceuticals will participate in this event as an exhibitor together with nine other MDPI journals, among which Pharmaceuticals, Journal of Personalized Medicine and Biomedicines will have journal representatives at our booth.

The following MDPI journals will be represented:

• Pharmaceuticals (leading journal);
• Biomedicines;
• JPM;
• JCM;
• Marine Drugs;
• Children;
• Current Oncology;
• BioMedInformatics;
• JoX;
• Rheumato.

If you are attending this conference, please feel free to start a conversation with us at our booth #A22. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://wcp2023.org/ or contact the Pharmaceuticals Editorial Office at pharmaceuticals@mdpi.com.

MDPI will be attending the Chinese Academic Conference on Tumor Biomarker, held in Shanghai, China, from 7 to 9 April 2023. This conference aims to achieve an in-depth exchange of the latest research results in the field of basic research, clinical application, cutting-edge technology, and industrial development in the field of tumor markers over the year. During this conference, MDPI will welcome researchers from different backgrounds to visit and share their latest inspirations with us.

The following MDPI journals will be represented:

• Biomedicines;
• Cancers;
• Cells;
• Diagnostics;
• Current Oncology;
• JPM;
• JCM;
• Onco;
• CIMB;
• BioMedInformatics.

If you plan on attending this conference, feel free to stop by our booth, #B155. Our delegates look forward to meeting you in person to answer any questions you may have.

For more information about the conference, please follow the link below: https://biomarker2022.sciconf.cn/cn/web/index/13496.

As a leading open access publisher, MDPI provides scholars with a high-quality and rich academic exchange platform by continuously expanding into new and exciting research areas.

In December 2022, MDPI launched five new journals, covering multiple subjects such as life sciences, biology, medicine and pharmacology, social sciences and humanities. These new journals are being edited by established scholars across the world.

If you are interested in creating more open access journals with us to publish cutting-edge research, please send your journal proposal application to newjournal-committee@mdpi.com.